July 16th, 2013
Follow-up after Barrett esophagus ablation: How do you do it, and when do you stop (if ever)?
We have shifted the paradigm of treating neoplastic Barrett esophagus (BE) away from a choice between intensive surveillance or surgery and towards endoscopic ablation. In the last 5 years, I have done hundreds of BE ablations using radiofrequency ablation (RFA) and endoscopic mucosal resection (EMR), and many thousands have been performed worldwide. However, on post-ablation surveillance, evidence is lacking on whether and when patients can be cut loose. Moreover, I am beginning to see patients who were believed to be cured after ablation (no signs of BE or neoplasia during years of surveillance) showing up with adenocarcinoma in the distal esophagus 4 or more years later.
Until now, I have been telling my patients that once they are BE- and dysplasia-free, I want them to undergo surveillance every 4 months for 1 year, then every 6 months for 1 year, then yearly for a couple of years, and then every other year if things remain stable.
But given the uncertainties I’ve outlined above, I am interested in discussing your practices and recommendations for surveillance after ablation for BE.
On that note, what would your approach be in the following cases?
1) If a patient with high-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
2) If a patient with low-grade dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
3) If a patient with NO dysplasia has their BE completely ablated (no BE and no dysplasia), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
4) Do you ever tell patients that they are cured and no longer need surveillance (e.g., after 5 years, after 10 years, etc.)?
5) If a patient with dysplasia has their neoplastic BE completely ablated (no dysplasia but residual BE), what surveillance period do you recommend for the following year? Year two? Beyond 2 years?
Please join the discussion to shed some light on this issue.
Categories: Barrett esophagus, cancer surveillance, Patient care, practice environment, Uncategorized
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

M. Brian Fennerty, MD
Founding Editor
NEJM Journal Watch Gastroenterology
Learn more about Gut Check on Gastroenterology.
Search the Archive
Archives by Date
From NEJM: Recently in Gastroenterology- Global Cholera-Control Efforts — Progress and Remaining Challenges June 11, 2026If the current cholera pandemic, which began in 1961, is ever to end, the world will need better cholera vaccines that are effective in young children and global access to safe water and adequate sanitation.
- Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation June 11, 2026The authors describe the scientific foundations of a study implicating autoantibodies against interleukin-10 in persons with inflammatory bowel disease.
- Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease June 11, 2026Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele.
- Dysphagia Lusoria June 4, 2026A 44-year-old man presented with a 4-year history of choking episodes while eating. Endoscopy revealed narrowing of the upper esophagus by a pulsating, cordlike structure in the posterior wall (shown in a video).
- Fasting, Glucocorticoids, and Breast Cancer June 4, 2026A study dissects the way in which fasting or a fasting-mimicking diet augments the effect of hormonal therapy in a mouse model of breast cancer.
- Global Cholera-Control Efforts — Progress and Remaining Challenges June 11, 2026
-
Tag Cloud
- Ambulatory endoscopy center antiretroviral therapy Barrett esophagus boceprevir bowel preparation CMS colitis colonoscopy colorectal cancer screening CT colonography DDW drug interactions efavirenz endoscopist Endoscopy gastroenterology GI bleeding hepatitis HIV IBS Irritable Bowel Syndrome Medicare midazolam nurse Plavix PPIs primary care probiotics ritonavir Screening colonoscopy sedation sigmoidoscopy telaprevir training virtual colonoscopy
